McCurdy Rebekah, Jiang Xuezhi, Clarkson Thomas B, Nudy Matthew, Schnatz Peter F
1Department of ObGyn 2Department of Internal Medicine, Reading Hospital, Reading, PA 3Department of ObGyn 4Department of Internal Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 5Department of Pathology/Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC. *Deceased.
Menopause. 2016 May;23(5):481-7. doi: 10.1097/GME.0000000000000582.
To analyze vitamin D3 plasma concentrations among monkeys randomized to oral conjugated equine estrogen (CEE) versus control and the association with coronary artery atherosclerosis (CAA).
Surgically postmenopausal monkeys (N = 50) were fed an atherogenic diet containing a woman's equivalent of 1000 IU/day of vitamin D3. The monkeys were randomized at baseline to receive CEE (equivalent of 0.45 mg/d, n = 25) or placebo (n = 25). 25-hydroxyvitamin D3 (25OHD3) was measured at baseline and 20 months later. At 20 months, CAA evidence of coronary artery remodeling, and American Heart Association (AHA) severity scores were assessed.
The percent change in 25OHD3 concentrations from baseline to 20 months postrandomization was inversely correlated with plaque area of the right coronary artery (P = 0.048), left circumflex artery (P = 0.039), left anterior descending artery (P = 0.017), and AHA severity score (AHA LADmax) (P = 0.016). Those with increased 25OHD3 concentrations who were taking CEE also had significantly lower AHA scores compared with those who were not taking CEE and did not have an increase in 25OHD3 (P = 0.01).
Monkeys with increases in 25OHD3 concentrations had significantly less severe CAA. Those with increases in 25OHD3 with CEE were associated with significantly decreased AHA lesion scores, decreased plaque, and greater coronary artery remodeling. If these findings are present in women, achieving higher 25OHD3 concentrations (or being a vitamin D supplementation "responder") may be associated with cardioprotection, and further studies to evaluate a synergistic effect with CEE and vitamin D on cardiovascular health are needed.
分析随机接受口服共轭马雌激素(CEE)与对照组的猴子的血浆维生素D3浓度,以及其与冠状动脉粥样硬化(CAA)的关联。
对手术绝经后的猴子(N = 50)喂食含相当于女性每日1000 IU维生素D3的致动脉粥样化饮食。猴子在基线时随机分为接受CEE(相当于0.45 mg/d,n = 25)或安慰剂(n = 25)。在基线和20个月后测量25-羟维生素D3(25OHD3)。在20个月时,评估冠状动脉重塑的CAA证据以及美国心脏协会(AHA)严重程度评分。
从基线到随机分组后20个月,25OHD3浓度的百分比变化与右冠状动脉斑块面积(P = 0.048)、左旋支动脉(P = 0.039)、左前降支动脉(P = 0.017)以及AHA严重程度评分(AHA LADmax)(P = 0.016)呈负相关。与未服用CEE且25OHD3未升高的猴子相比,服用CEE且25OHD3浓度升高的猴子的AHA评分也显著更低(P = 0.01)。
25OHD3浓度升高的猴子的CAA严重程度显著更低。服用CEE且25OHD3浓度升高的猴子与AHA病变评分降低、斑块减少以及冠状动脉重塑增加相关。如果这些发现也存在于女性中,达到更高的25OHD3浓度(或成为维生素D补充剂“反应者”)可能与心脏保护相关,并且需要进一步研究来评估CEE与维生素D对心血管健康的协同作用。